A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.

NCT00929370 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
34
Enrollment
INDUSTRY
Sponsor class

Stopped Study has now been terminated due to changes in project strategy. Current available data will be analysed and reported in a synoptic study report.

Conditions

Interventions

Sponsor

GlaxoSmithKline